DANAHER CORP /DE/
DHRAPI behind this page
DHR Q3 2025 request
Playground key active
/api/financials?ticker=DHR&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 6,053 | 5,798 | +4.4% |
Show Product Lines breakouts |
|||
| Nonrecurring revenue | 1,036 | 1,021 | +1.5% |
| Nonrecurring revenue · Biotechnology | 208 | 231 | -10.0% |
| Nonrecurring revenue · Diagnostics | 252 | 236 | +6.8% |
| Nonrecurring revenue · Life Sciences | 576 | 554 | +4.0% |
| Recurring revenue | 5,017 | 4,777 | +5.0% |
| Recurring revenue · Biotechnology | 1,590 | 1,422 | +11.8% |
| Recurring revenue · Diagnostics | 2,211 | 2,127 | +3.9% |
| Recurring revenue · Life Sciences | 1,216 | 1,228 | -1.0% |
Show Business Segments breakouts |
|||
| Biotechnology · High-growth markets | 498 | 485 | +2.7% |
| Biotechnology · North America | 624 | 503 | +24.1% |
| Biotechnology · Operating Segments | 1,798 | 1,653 | +8.8% |
| Biotechnology · Other developed markets | 89 | 78 | +14.1% |
| Biotechnology · Western Europe | 587 | 587 | 0.0% |
| Diagnostics · High-growth markets | 721 | 737 | -2.2% |
| Diagnostics · North America | 1,228 | 1,157 | +6.1% |
| Diagnostics · Operating Segments | 2,463 | 2,363 | +4.2% |
| Diagnostics · Other developed markets | 97 | 101 | -4.0% |
| Diagnostics · Western Europe | 417 | 368 | +13.3% |
| Life Sciences · High-growth markets | 542 | 501 | +8.2% |
| Life Sciences · North America | 728 | 796 | -8.5% |
| Life Sciences · Operating Segments | 1,792 | 1,782 | +0.6% |
| Life Sciences · Other developed markets | 130 | 120 | +8.3% |
| Life Sciences · Western Europe | 392 | 365 | +7.4% |
Show Geography breakouts |
|||
| High-growth markets | 1,761 | 1,723 | +2.2% |
| North America | 2,580 | 2,456 | +5.0% |
| Other developed markets | 316 | 299 | +5.7% |
| Western Europe | 1,396 | 1,320 | +5.8% |
| Cost of Revenue | -2,530 | -2,397 | -5.5% |
| Gross Profit | 3,523 | 3,401 | +3.6% |
| Selling, General & Administrative | -1,991 | -2,060 | +3.3% |
| Research & Development | -378 | -383 | +1.3% |
| Operating Income | 1,154 | 958 | +20.5% |
Show Business Segments breakouts |
|||
| Biotechnology · Operating Segments | 352 | 390 | -9.7% |
| Diagnostics · Operating Segments | 665 | 615 | +8.1% |
| Life Sciences · Operating Segments | 222 | 35 | +534.3% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -85 | -82 | -3.7% |
| Other Non-Operating Income (Expense) | -14 | 102 | -113.7% |
| Interest Expense | -67 | -87 | +23.0% |
| Interest Income | 3 | 4 | -25.0% |
| Income Before Taxes | 1,076 | 977 | +10.1% |
| Income Tax Expense (Benefit) | -168 | -159 | -5.7% |
| Net Income | 908 | 818 | +11.0% |
Show Equity Components breakouts |
|||
| Retained Earnings | 908 | 818 | +11.0% |
| EPS (Basic) | 1.28 | 1.13 | +13.3% |
| EPS (Diluted) | 1.27 | 1.12 | +13.4% |
| Wtd Avg Shares (Basic) | 710.7 | 723 | -1.7% |
| Wtd Avg Shares (Diluted) | 713.7 | 729.4 | -2.2% |
| Comprehensive Income | 887 | 2,099 | -57.7% |
| Gain Loss On Investments | -15 | 103 | -114.6% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,528 | 2,627 | -41.8% |
| Accounts Receivable | 3,755 | 3,507 | +7.1% |
| Inventory Finished Goods Net Of Reserves | 1,373 | 1,353 | +1.5% |
| Inventory Work In Process Net Of Reserves | 526 | 498 | +5.6% |
| Inventory Raw Materials Net Of Reserves | 775 | 827 | -6.3% |
| Inventory | 2,674 | 2,678 | -0.1% |
| Prepaid Expenses & Other Current Assets | 1,649 | 1,248 | +32.1% |
| Total Current Assets | 9,606 | 10,060 | -4.5% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 5,376 | 4,843 | +11.0% |
| Other Non-Current Assets | 3,870 | 3,685 | +5.0% |
| Goodwill | 42,948 | — | — |
Show Business Segments breakouts |
|||
| Biotechnology · Operating Segments | 23,145 | — | — |
| Diagnostics · Operating Segments | 6,966 | — | — |
| Life Sciences · Operating Segments | 12,837 | — | — |
| Total Assets | 79,897 | — | — |
Show Business Segments breakouts |
|||
| Biotechnology · Operating Segments | 37,296 | — | — |
| Diagnostics · Operating Segments | 14,653 | — | — |
| Life Sciences · Operating Segments | 23,179 | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 4,769 | — | — |
| Operating Lease Right-of-Use Assets | 1.2 | 1.2 | 0.0% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 18,097 | 19,854 | -8.8% |
| Current Liabilities | |||
| Debt Current | 23 | 1,200 | -98.1% |
| Accounts Payable Trade Current | 1,698 | 1,596 | +6.4% |
| Accrued Liabilities | 4,603 | 4,543 | +1.3% |
| Total Current Liabilities | 6,324 | 7,339 | -13.8% |
| Non-Current Liabilities | |||
| Other Non-Current Liabilities | 5,660 | 5,647 | +0.2% |
| Long-Term Debt | 16,833 | — | — |
Show Debt Instrument breakouts |
|||
| Euro Denominated Commercial Paper and 2026 Biopharma Euro Notes | 2.6 | — | — |
| Long-Term Debt | 16,856 | 17,524 | -3.8% |
Show Debt Instrument breakouts |
|||
| 0.2% senior notes due 2026 · Senior Notes | 1,462 | 1,393 | +5.0% |
| 0.3% senior notes due 2027 · Senior Notes | 206 | 216 | -4.6% |
| 0.45% senior notes due 2028 · Senior Notes | 1,460 | 1,390 | +5.0% |
| 0.65% senior notes due 2032 · Senior Notes | 355 | 373 | -4.8% |
| 0.75% senior notes due 2031 · Senior Notes | 2,041 | 1,945 | +4.9% |
| 1.125% senior bonds due 2028 · Bonds | 265 | 252 | +5.2% |
| 1.2% senior notes due 2027 · Senior Notes | 701 | 668 | +4.9% |
| 1.35% senior notes due 2039 · Senior Notes | 1,450 | 1,382 | +4.9% |
| 1.8% senior notes due 2049 · Senior Notes | 870 | 829 | +4.9% |
| 2.1% senior notes due 2026 · Senior Notes | 936 | 892 | +4.9% |
| 2.5% senior notes due 2030 · Senior Notes | 936 | 893 | +4.8% |
| 2.6% senior notes due 2029 · Senior Notes | 798 | 797 | +0.1% |
| 2.6% senior notes due 2050 · Senior Notes | 982 | 982 | 0.0% |
| 2.8% senior unsecured notes due 2051 · Senior Notes | 985 | 985 | 0.0% |
| 3.25% senior notes due 2039 · Senior Notes | 892 | 891 | +0.1% |
| 3.4% senior notes due 2049 · Senior Notes | 891 | 890 | +0.1% |
| 4.375% senior notes due 2045 · Senior Notes | 500 | 499 | +0.2% |
| Euro-denominated commercial paper · Commercial Paper | 933 | 930 | +0.3% |
| Other | 34 | 9 | +277.8% |
| Stockholders' Equity | |||
| Common Stock | 9 | 9 | 0.0% |
| Additional Paid In Capital Common Stock | 17,076 | 9,304 | +83.5% |
| Treasury Stock Common Value | -11,344 | — | — |
| Retained Earnings | 45,920 | 43,296 | +6.1% |
| Accumulated Other Comprehensive Income | -590 | — | — |
| Total Stockholders' Equity | 51,071 | 51,299 | -0.4% |
| Minority Interest | 9 | 6 | +50.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 51,080 | 51,305 | -0.4% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -295 | -395 | +25.3% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 203 | 142 | +43.0% |
| Accumulated Other Comprehensive Income | -590 | -1,310 | +55.0% |
| Accumulated Translation Adjustment | -498 | -1,057 | +52.9% |
| Additional Paid In Capital | 17,076 | 16,641 | +2.6% |
| Common Stock | 9 | 9 | 0.0% |
| Noncontrolling Interest | 9 | 6 | +50.0% |
| Retained Earnings | 45,920 | 43,296 | +6.1% |
| Treasury Stock Common | -11,344 | -7,337 | -54.6% |
| Total Liabilities & Equity | 79,897 | 80,615 | -0.9% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 555 | 534 | +3.9% |
Show Business Segments breakouts |
|||
| Biotechnology · Operating Segments | 110 | 113 | -2.7% |
| Diagnostics · Operating Segments | 301 | 292 | +3.1% |
| Life Sciences · Operating Segments | 137 | 123 | +11.4% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 7 | 6 | +16.7% |
| Amortization Of Intangible Assets | 1,269 | 1,223 | +3.8% |
Show Business Segments breakouts |
|||
| Biotechnology · Operating Segments | 672 | 650 | +3.4% |
| Diagnostics · Operating Segments | 144 | 145 | -0.7% |
| Life Sciences · Operating Segments | 453 | 428 | +5.8% |
| Stock-Based Compensation | 235 | 231 | +1.7% |
| Investment Gains Losses And Pretax Gain On Sale Of Product Line | 140 | -7 | +2100.0% |
| Asset Impairment Charges | 548 | 222 | +146.8% |
Show Business Segments breakouts |
|||
| Biotechnology and Diagnostics · Technology Based Intangible Assets | 101 | — | — |
| Biotechnology · Building | 15 | — | — |
| Biotechnology · Operating Segments | 101 | — | — |
| Diagnostics · Operating Segments | 15 | — | — |
| Life Sciences · Operating Segments | 432 | 222 | +94.6% |
| Life Sciences · Trade Names | 432 | 222 | +94.6% |
| Change in Accounts Receivable | -65 | 482 | -113.5% |
| Change in Inventory | -242 | -117 | -106.8% |
| Change in Accounts Payable | -134 | -186 | +28.0% |
| Change in Prepaid & Other Assets | -53 | 299 | -117.7% |
| Increase Decrease In Other Accounts Payable And Accrued Liabilities | -371 | -850 | +56.4% |
| Net Cash from Operations | 4,299 | 4,669 | -7.9% |
| Investing Activities | |||
| Capital Expenditures | -785 | -876 | +10.4% |
| Proceeds From Sale Of Property Plant And Equipment | 10 | 12 | -16.7% |
| Payments To Acquire Investments | -79 | -188 | +58.0% |
| Proceeds From Sale Maturity And Collections Of Investments | 12 | 251 | -95.2% |
| Proceeds From Sale Of Product Line | 9 | — | — |
| Other Investing Activities | 21 | 39 | -46.2% |
| Net Cash from Investing | -812 | -1,287 | +36.9% |
| Financing Activities | |||
| Payments For Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 39 | 143 | -72.7% |
| Payments Of Dividends | -652 | -573 | -13.8% |
| Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less | 22 | 1 | +2100.0% |
| Proceeds From Debt Maturing In More Than Three Months | 4 | — | — |
| Repayments Of Debt Maturing In More Than Three Months | -500 | -974 | +48.7% |
| Share Repurchases | -3,088 | -5,170 | +40.3% |
| Proceeds From Payments For Other Financing Activities | -108 | -120 | +10.0% |
| Net Cash from Financing | -4,283 | -6,693 | +36.0% |
| Supplemental | |||
| Interest Paid | 231 | 280 | -17.5% |
| Income Taxes Paid | 808 | 933 | -13.4% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 246 | 74 | +232.4% |
| Net Change in Cash | -550 | -3,237 | +83.0% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.